Clinical Trial

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Study acronym: HOVON 136 NHL
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2020 (before its estimated January 2023 completion). Its status may not reflect the trial's current state.
Summary
Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy and ASCT.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2017-11-22.
Status change: Not Yet Recruiting → Recruiting 2020-12-09
Trial Details
NCT Number NCT03356054
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions DLBCL
Enrollment 37 participants
Start Date 2018-03-05
Primary Completion 2023-01 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2020-12-10